Close Menu

NEW YORK (360Dx) – Nonprofit organization PATH said on Wednesday it is partnering with SD Biosensor to further develop a diagnostic test in support of efforts to eliminate malaria.

The two entities have developed the Standard G6PD test to guide clinical care of patients with Plasmodium vivax malaria who also have a hereditary enzyme deficiency that can result in severe anemia if they are treated with 8-aminoquinoline-based drugs for the infection. The deficiency is known as glucose-6-phosphate-dehydrogenase (G6PD) deficiency.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.